HIMS Jun 2024 14.500 put
| Previous close | 0.1600 |
| Open | 0.1600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 14.50 |
| Expiry date | 2024-06-14 |
| Day's range | 0.1600 - 0.1600 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Nvidia earnings, housing market outlook, BNPL regulatory pressure: Market Domination
On today's episode of Market Domination, Yahoo Finance hosts Julie Hyman and Josh Lipton break down the trading day's biggest stories and latest trends. Nvidia (NVDA) topped earnings expectations and announced a 10-to-1 stock split. Will McGough, Director of Investments at Prime Capital Investment Advisors says the company's AI play "has huge implications across multiple markets." RBC Capital Markets Software Equity Analyst Rishi Jaluria adds, "80% of CIOs are telling us that they are either currently in production or expect to be in production with AI over the next 12 months, so the appetite is real, the use cases are real." Macquarie Head of US AI and Software Research Frederick Havemeyer notes that cybersecurity companies will benefit from the AI race, pointing to CrowdStrike (CRWD), which he believes will see growth as the competition heats up. New housing data reveals that April home sales fell below estimates, declining more than expected: a 1.9% drop month over month. Realtor.com Chief Economist Danielle Hale expects the real estate market and buyer activity to "ramp up" with every mortgage rate dip but forecasts a "slow comeback" overall. Goldman Sachs upgraded Shopify (SHOP) to Buy from Neutral, raising its price target on the stock to $74 from $67. Meanwhile, Citigroup downgraded Hims & Hers Health (HIMS) to Neutral from Buy and raised its price target to $20 from $16. Buy now, pay later (BNPL) stocks (AFRM, PYPL, SQ) are under pressure after the Consumer Financial Protection Bureau proposed a new rule that would force lenders to adhere to the same consumer protections as credit cards. This post was written by Melanie Riehl
- Yahoo Finance Video
Citigroup downgrades Hims & Hers Health to Neutral from Buy
Citigroup has downgraded Hims & Hers Health (HIMS) to Neutral from Buy and raised its price target to $20 from $16. Yahoo Finance's Julie Hyman and Josh Lipton explain how this move is affecting the company's stock valuation. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
- Yahoo Finance Video
Investors await Nvidia earnings, commodities on the rise: Morning Brief
On today's episode of The Morning Brief, Yahoo Finance Hosts Seana Smith and Brad Smith break down some of the market's (^DJI, ^IXIC, ^GSPC) biggest stories and give an overview of the trading week ahead. The stock market opened mixed on Monday, with the Dow Jones Industrial Average opening below its recent record high of 40,000. Morgan Stanley's Michael Wilson, previously bearish on S&P 500 growth, is now bullish on the index's potential, revising his target from 4,500 to 5,400. Meanwhile, metal commodities continue to surge after gold (GC=F) and silver futures (SI=F) reached fresh highs last week. BofA Global Research Head of Metals Research Michael Widmer explains that precious metals are in a "buy-the-dip market." Nvidia (NVDA) is set to post its first quarter earnings for the fiscal 2025 year on Wednesday. Moor Insights & Strategy Founder and CEO Patrick Moorhead believes the chip company will outperform expectations, citing increasing demand as the artificial intelligence race heats up. AI is increasingly becoming a trend, as the number of times AI has been mentioned on earnings calls this quarter has notably risen compared to last quarter, according to Goldman Sachs Investment Research. Veteran market strategist and founder of RandyFrederickMedia.com Randy Frederick adds that "AI is going to change things as much as the Internet did when it came about 30, 40 years ago." All eyes are on Paramount (PARA, PARAA) as Sony (SONY) and Apollo Global (APO) have reportedly signed non-disclosure agreements in their latest efforts to court the media giant. On the healthcare front, Hims & Hers Health (HIMS) stock has jumped on the announcement that the telehealth provider will introduce compounding injectable GLP-1 weight-loss drugs to its services. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Melanie Riehl
